Back to search

Article

DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-small Lung Cancer

2020-08-09

Abstract excerpt

Erlotinib inhibits epithelial growth factor receptor (EGFR) kinase activity and is used to treat non-small cell lung cancer (NSCLC). Despite its high efficacy, recurrence can occur in patients who become resistant to the drug. To address the underlying mechanism of Erlotinib resistance, we investigated additional mechanisms related to mode-of-drug-action, by multiple protein-binding interactions, besides EGFR by u...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
df331558-e2e6-5094-8603-f39478034182
DOI
10.20944/preprints202008.0222.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-small Lung CancerDOI 10.20944/preprints202008.0222.v1
Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.Semantic proximity
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.Semantic proximity
The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.Semantic proximity
Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cellsSemantic proximity
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.Semantic proximity
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity
Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.Semantic proximity
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity
Select a neighboring publication to make it the new centre.